Novan Provides Update on SB204 Development Program
March 06, 2017 06:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 06, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that, after further analysis of the results from the NI-AC301 and NI-AC302...
Novan Announces SB204 Program Update Conference Call and Webcast
March 03, 2017 16:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 03, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company will host a conference call on Monday, Mar. 6, at 8 a.m....
Novan Licenses SB204 to Sato for Acne in Japan
January 17, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato...
Novan to Present Data from SB204 Phase 2b Trial at Fall Clinical Dermatology Conference
October 18, 2016 09:05 ET
|
Novan, Inc.
DURHAM, N.C., Oct. 18, 2016 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that results from the Company’s Phase 2b clinical trial to evaluate the efficacy...